AIM Vaccine Co., Ltd. Class H (HK:6660)
:6660
Want to see HK:6660 full AI Analyst Report?
Top Page
AIM Vaccine Co., Ltd. Class H
(6660)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$2.00
▼(-42.69% Downside)
Action:Reiterated
Date:06/06/26
The score is held down primarily by weak financial performance (ongoing losses, shrinking 2025 revenue, and persistent negative free cash flow) and a bearish technical setup (price below all key moving averages with negative MACD). Valuation provides limited support because the negative P/E reflects losses and no dividend yield is available.
Positive Factors
High gross margins
Sustained gross margins near 62–74% indicate the company captures strong product-level economics from vaccine manufacturing. That margin buffer supports long-term profitability potential if operating costs and commercial scale are managed, and reflects durable manufacturing or product advantages in biologics.
Negative Factors
Persistent net losses
Deep negative net margins reflect operating cost structure and commercialization shortfalls. Sustained losses erode equity and limit reinvestment capacity, making it harder to self-fund growth or new product launches and increasing reliance on funding or dilution if profitability is not restored.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 62–74% indicate the company captures strong product-level economics from vaccine manufacturing. That margin buffer supports long-term profitability potential if operating costs and commercial scale are managed, and reflects durable manufacturing or product advantages in biologics.
Read all positive factors
AIM Vaccine Co., Ltd. Class H (6660) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.66B
Dividend YieldN/A
Average Volume (3M)1.38M
Price to Earnings (P/E)―
Beta (1Y)2.47
Revenue Growth-9.18%
EPS Growth-142.22%
CountryHK
Employees1,535
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.55
Shares Outstanding507,673,700
10 Day Avg. Volume830,500
30 Day Avg. Volume1,376,953
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.28
Price to Sales (P/S)3.03
P/FCF Ratio-20.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)HK$3.68B
AIM Vaccine Co., Ltd. Class H Business Overview & Revenue Model
Company Description
AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People's Republic of China. The company's product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and M...
How the Company Makes Money
AIM Vaccine makes money primarily by selling vaccine products and related biologics. Its revenue model is driven by (1) product sales to healthcare channels (including public-sector procurement and/or commercial distribution, depending on product ...
AIM Vaccine Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17B | 1.29B | 1.19B | 1.26B | 1.57B |
| Gross Profit | 760.20M | 953.51M | -611.21M | 1.03B | 1.29B |
| EBITDA | -89.41M | -98.83M | -2.05B | -242.03M | -451.71M |
| Net Income | -675.46M | -277.23M | -1.30B | -319.60M | -692.77M |
Balance Sheet | |||||
| Total Assets | 6.55B | 7.31B | 7.26B | 8.88B | 8.07B |
| Cash, Cash Equivalents and Short-Term Investments | 384.72M | 594.87M | 736.41M | 818.91M | 746.74M |
| Total Debt | 1.76B | 1.84B | 1.80B | 1.40B | 650.43M |
| Total Liabilities | 3.46B | 3.70B | 3.37B | 3.01B | 2.37B |
| Stockholders Equity | 2.76B | 3.37B | 3.64B | 4.96B | 4.89B |
Cash Flow | |||||
| Free Cash Flow | -171.39M | -139.09M | -467.14M | -966.96M | -1.05B |
| Operating Cash Flow | 67.47M | 99.19M | -165.50M | -110.32M | 93.40M |
| Investing Cash Flow | -107.73M | -162.34M | -271.96M | -858.15M | -1.34B |
| Financing Cash Flow | -111.65M | -26.22M | 362.07M | 980.37M | 788.02M |
AIM Vaccine Co., Ltd. Class H Technical Analysis
Negative
3.49
Price Trends
2.60
Negative
2.92
Negative
3.50
Negative
Market Momentum
-0.12
Positive
32.94
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6660, the sentiment is Negative. The current price of 3.49 is above the 20-day moving average (MA) of 2.48, above the 50-day MA of 2.60, and below the 200-day MA of 3.50, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 32.94 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6660.
AIM Vaccine Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$44.35B | 24.56 | 11.22% | 1.04% | 16.83% | -8.65% | |
64 Neutral | HK$134.25B | 24.28 | 10.64% | ― | 16.79% | 47.14% | |
54 Neutral | HK$28.28B | -6.75 | -12.72% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$779.55M | -3.15 | -14.48% | ― | ― | 55.86% | |
44 Neutral | HK$2.66B | -3.29 | -22.28% | ― | -9.18% | -142.22% | |
43 Neutral | HK$2.34B | -9.48 | 11.40% | ― | -90.96% | 77.66% |
* Healthcare Sector Average
HK:6660
AIM Vaccine Co., Ltd. Class H
2.10
-1.90
-47.50%
HK:1548
Genscript Biotech
12.92
-4.06
-23.91%
HK:2269
Wuxi Biologics (Cayman)
32.74
6.74
25.92%
HK:2137
Brii Biosciences Limited
1.10
-0.79
-41.80%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
16.47
0.40
2.51%
HK:2197
Clover Biopharmaceuticals Ltd.
1.74
1.50
625.00%
AIM Vaccine Co., Ltd. Class H Corporate Events
AIM Vaccine Books Impairments as It Pauses mRNA Rabies Projects and Delays PCV13 Launch
Jun 5, 2026
AIM Vaccine has provided additional detail on impairment losses recorded for 2025, stemming from strategic changes in its mRNA and pneumococcal vaccine programs. The group is reassessing its RD priorities and financial expectations as evolving reg...
AIM Vaccine Seeks Shareholder Nod for RMB Share Issue and Dual Listing on NEEQ and Beijing Bourse
May 21, 2026
AIM Vaccine Co., Ltd. plans to convene its first extraordinary general meeting of 2026 in Shanghai to seek shareholder approval for a private issuance of up to 40 million unlisted RMB ordinary shares and their listing on the National Equities Exch...
AIM Vaccine Reshapes Board with New Director Nominations After Resignation
May 18, 2026
AIM Vaccine Co., Ltd. announced the resignation of independent non-executive director Ms. Jie Wen, who also served on the audit, remuneration and appraisal, and nomination committees, citing a change in work arrangements and indicating no disagree...
AIM Vaccine Sets 2025 AGM to Approve Results, Board Changes and Capital Mandates
May 18, 2026
AIM Vaccine Co., Ltd. has called its 2025 annual general meeting for June 10, 2026, in Shanghai, where shareholders will review the directors’ report, 2025 annual report, final accounts and audited financial statements, and authorize the boa...
AIM Vaccine Swings to Deeper 2025 Loss on Impairments and Revenue Decline
Mar 30, 2026
AIM Vaccine Co., Ltd. reported a decline in revenue to RMB1.17 billion for 2025, down 9.3% from the prior year, with gross profit falling 20.3% to RMB760.2 million. The vaccine maker remains focused on its core product portfolio in the competitive...
AIM Vaccine Plans Beijing A-Share Listing and New Domestic Share Issuance
Mar 30, 2026
AIM Vaccine Co., Ltd. has approved a plan to issue up to 40 million new domestic shares, representing just over 3% of its existing share capital, under a specific mandate to selected investors in China. The issuance, priced in an indicative range ...
AIM Vaccine Sets March 30 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 18, 2026
AIM Vaccine Co., Ltd., a Hong Kong-listed Chinese vaccine manufacturer, has announced that its board of directors will convene on March 30, 2026, to review and approve the consolidated annual results for the year ended December 31, 2025. The board...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.